Skip to content
Clinical Trials – home
Not yet recruiting

Long‑Term Safety and Effectiveness of 3-(7‑chloro‑1H‑indazol‑5‑yl)-2,5‑bis(trifluoromethyl)-3H‑imidazo[4,5‑b]pyridine in Adults with Refractory Focal Onset Epilepsy

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on adults with Epilepsy that is not controlled by other medicines, specifically focal onset seizures. These are seizures that start in one part of the brain. The investigational drug being examined is called RAP-219, taken as a tablet by mouth.

The main aim is to assess the long‑term safety and how well the medicine is tolerated when used over an extended period. Participants will take the study tablet regularly and will attend scheduled visits where doctors will check blood pressure, heart rhythm using an ECG, and basic blood work, as well as ask about any new symptoms or side effects.

Throughout the study, participants will keep a simple diary of seizure occurrences and will have periodic check‑ups that may include a brief physical exam, blood tests, and the heart rhythm test. The study will continue for many months to gather information on any changes in health and to see if the frequency of seizures changes compared with the start of the study.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Assessment

    After you join the study, you will undergo initial medical evaluations that include measurement of vital signs such as blood pressure and heart rate, an electrocardiogram (ECG) to record the heart’s electrical activity, and laboratory tests of blood to check complete blood count and serum chemistry.

    These assessments provide a reference point for later safety comparisons.

  2. Step 2

    Start of Open‑Label Treatment

    You will begin taking the study medication RAP‑219 in tablet form taken by mouth (oral route). The trial documentation lists the tablet dose as 0 mg, indicating that the exact amount will be assigned by the study protocol.

    You will take the tablet according to the schedule given by the study team and continue this throughout the long‑term treatment period.

  3. Step 3

    Seizure Diary Recording

    You will keep a daily record of any focal onset seizures you experience, noting the date, time, and duration of each event.

    The diary information is used to calculate the change in seizure frequency compared with the baseline period.

  4. Step 4

    Regular Safety Visits

    At scheduled intervals, you will return to the clinic for repeat measurements of vital signs, ECG, and blood laboratory tests.

    These visits allow monitoring for any adverse events and assessment of long‑term tolerability of RAP‑219.

  5. Step 5

    End‑of‑Study Assessment

    When the study concludes or if you discontinue early, you will undergo a final set of evaluations similar to the baseline assessments.

    The final data will be compared with the baseline to determine safety outcomes and changes in seizure frequency.

Who can join the trial?

8 criteria

  • Completed the double‑blind treatment period of the earlier RAP‑219 study (named RAP‑219‑FOS‑301 or ‑302) and was judged by the doctor to tolerate it well.
  • Will be able and willing to follow all parts of the study for its entire length, including taking whole RAP‑219 tablets by mouth, keeping a paper diary of seizures, and attending all scheduled check‑ups.
  • Women who could become pregnant must agree to use a highly effective form of birth control from the first dose of the study drug until the final study visit.
  • Has not taken part in any earlier clinical study of RAP‑219.
  • Is between 18 and 80 years old at the first study visit.
  • Has a diagnosis of focal epilepsy (a type of epilepsy that starts in one specific area of the brain) confirmed by the International League Against Epilepsy (ILAE) criteria and supported by at least one brain scan (MRI or CT) and an EEG (a test that records the brain’s electrical activity). The scans may look normal but must not suggest another cause.
  • Had at least one focal seizure recorded in a paper seizure diary during the baseline period after the first visit.
  • Is currently taking between 1 and 3 anti‑seizure medicines (ASMs) on a regular schedule, and the dose, strength, timing, and type of these medicines must stay the same as they were before the first visit (rescue medicines taken only as needed are not counted).

Who cannot join the trial?

11 criteria

  • You cannot join if you are already taking part in another study that tests a drug or device (an interventional study) before the first visit, or if you plan to be in such a study during this trial. Observational studies are allowed.
  • You cannot join if you work for, or are related to, an employee of the company that makes the drug (Sponsor) or the study site.
  • If you have taken the study drug RAP‑219 before, and the doctor believes that taking it again would be unsafe, you cannot join.
  • If you previously enrolled in earlier RAP‑219 studies (FOS‑301 or FOS‑302) and had frequent or severe dosing problems or did not follow study rules, you cannot join.
  • You cannot join if you are pregnant, are breastfeeding, or plan to become pregnant while the study is running.
  • You cannot join if you have had epilepsy surgery (brain surgery to treat seizures) before the first visit.
  • You cannot join if you currently have hepatic (liver) or renal (kidney) failure.
  • You cannot join if you are currently taking felbamate unless you have been on the same dose for at least 12 months and your liver tests and blood counts have stayed stable, or if you are taking vigabatrin unless you have been on the same dose for at least 24 months and have had normal vision tests for at least 12 months. (Both are medicines used to treat seizures.)
  • You cannot join if you have a recent or current problem with drug or alcohol abuse, or if a drug test at the first visit is positive (except for cannabis or prescribed medicines).
  • You cannot join if you are already participating, or plan to participate, in another clinical trial that uses an investigational drug or device before the first visit. Observational studies are allowed.
  • You cannot join if you are allergic (hypersensitive) to RAP‑219 or any of its inactive ingredients (excipients).
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

RAP-219 is an experimental oral tablet being tested in this study. It contains a new chemical compound that has not yet been given a commercial name. Participants will take the tablet by mouth, and the researchers will watch closely for any side effects or safety concerns over a long period. The main goal is to see whether RAP-219 can be used safely in adults whose focal seizures have not been controlled by other medicines.

What is already known about the treatment

RAP-219 (3-(7-chloro-1H-indazol-5-yl)-2,5-bis(trifluoromethyl)-3H-imidazo[4,5-b]pyridine) - The drug is taken orally as a tablet that participants swallow with water. It is still an investigational compound and has not been approved for general medical use, appearing mainly in early‑phase clinical trial reports. RAP‑219 is being studied to treat adults with refractory focal onset seizures associated with epilepsy. It works by selectively blocking voltage‑gated sodium channels in brain neurons, which helps calm the excessive electrical activity that leads to seizures, and it is classified as an experimental antiepileptic agent.

Investigated diseases

Epilepsy - Epilepsy is a neurological disorder that causes repeated seizures. Focal seizures begin in a specific area of the brain and may spread to other regions. In some patients the seizures do not respond to standard medicines, which is called refractory epilepsy. Over time, the frequency or pattern of seizures can change, sometimes becoming more frequent. The condition can interfere with daily activities and overall quality of life.
Trial detailsLast updated 21 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2026-525735-17-00Protocol codeRAP-219-FOS-901Estimated enrolment822 patientsSponsorRapport Therapeutics Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.